Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A

NCT06961500 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

133

Enrollment

OTHER

Sponsor class

Conditions

Follicular Lymphoma Grade 3A

Interventions

DRUG: Obinutuzumab
DRUG: CHOP
DRUG: Bendamustine

Sponsor

Sun Yat-sen University